Adamas Pharmaceuticals (ADMS) PT Lowered to $12 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Nvidia to commit $3 bln to Meta share offering as part of bigger AI partnership
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Boeing free cash flow beats estimates despite production challenges
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Price: $8.22 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 16
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 16
Join SI Premium – FREE
Piper Jaffray analyst David Amsellem lowered the price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $12.00 (from $16.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Galaxy Digital (GLXY) PT Lowered to $35 at BTIG
- Alps Alpine Co Ltd. (6770:JP) (APELF) PT Lowered to JPY2,460 at Nomura/Instinet
- Hokuhoku Financial Group (8377:JP) PT Raised to JPY920 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
